Call your doctor before leaving home if you think you’ve been exposed to COVID-19 or have symptoms

Due to the presence of COVID-19 in our community, visitor restrictions are in place for all Duke clinics and hospitals. For your safety and the safety of others, we recommend patients do not bring a visitor to Duke clinics, if at all possible. If a visitor must accompany a patient, only one individual over 12 years of age is allowed. Patients and visitors will be screened for symptoms upon arrival. Individuals with flu-like symptoms are not allowed. View the complete list of Visitor Restrictions.

Effective immediately, Duke Health is prioritizing and rescheduling some non-emergent or non-critical surgeries, procedures, and appointments. Check our COVID-19 (Coronavirus) page for updates.

MERCK CMV MK-8228 LET (Kidney Transplant) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn more about the study drug (Letermovir) and how it can help keep people from getting Human Cytomegalovirus (CMV) disease.
What is the Condition Being Studied?
Kidney Transplant

Who Can Participate in the Study?

Adults who:
- Have had or will have a kidney transplant within 7 days of signing up for the study

Age Group

What is Involved?

If you choose to join this study, you will:
- Be randomized (like flipping a coin) to Group 1 or Group 2
-- Group 1 will get the study drug, Letermovir (LET)
-- Group 2 will get the standard of care medicine, Valganciclovir (VGCV)
- Both groups will also be asked to give blood

Study Details

Full Title
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) Versus Valganciclovir for the Prevention of Human Cytomegalovirus (CMV) Disease in Adult Kidney Transplant Recipients
Principal Investigator
Kidney/Pancreas Transplant Surgeon
Protocol Number
IRB: PRO00090050
NCT: NCT03443869
Phase III
Contact the Duke Recruitment Innovation Center